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INTRODUCTION:  Chordomas  are  rare,  slow  growing,  locally  destructive  bone  tumours  arising  from  the
notochord.
PRESENTATION  OF CASE:  Presenting  a case  of  a 65  year  old  man,  who  presented  with  complaints  of  swelling
on the  right  lower  back  for 1 year  associated  with  pain.
On,  physical  examination,  a swelling  measuring  5  cm  × 4 cm  was  noted  in  the  lower  back  with  posterior
wall  indentation  on  per  rectal  examination.
MRI revealed  a mass  lesion  involving  the  sacrum  (s3–s4)  and  coccyx.  FNAC  showed  features  of  a chroma.
At  surgery,  we excised  a  mass  from  the  retrorectal  space  and  biopsy  proved  it to  be  a  chondroid
chordoma,  a variant  of  chordoma.
DISCUSSION:  Chordomas  are  solid  malignant  tumours  that  arise  from  vestiges  of  the foetal  notochord.
Common  locations  are  the  clivus  and  the  sacrococcygeus  region.
Annual incidence  of  these  tumours  is 1 in  one  million.  MRI  is the  imaging  modality  of choice.  Prognosis
improves  based  on  the  age,  resected  margins  and  postoperative  treatment.
CONCLUSION:  Here,  we  shall  discuss  the  literature,  variants,  treatment  and  prognosis  of  this  rare  tumour.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction/background
Chordoma is a rare, low-grade malignant bone tumour arising
rom primitive notochord remnants of the axial skeleton.1 Their
ncidence rate is 0.1/100,000/year. Chordomas involve the sacro-
occygeal region in 50–60% of the cases and the clivus or the spheno
ccipital region in 30–35% cases.2 They account for over 40% of all
acral tumours. Local invasiveness and destructiveness are char-
cteristic features of the disease. Complete surgical excision is the
ain therapeutic modality able to effect a cure. The importance of
adiation has gradually increased overtime.3 Imaging techniques in
articular MRI, play a crucial role in surgical planning.
. Case presentation
Our patient was a 66-year-old male with complaints of swelling
ver his lower back for well over a year. The swelling was progres-
ively increasing in size and was associated with pain for 5 months.
n examination, a 6 cm × 8 cm ﬁrm, immobile swelling was noted
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over the sacrum. Per rectal examination revealed a indentation on
the posterior rectal wall.
3. Investigations
Blood investigations were done, which were within normal lim-
its.
An MRI  of the lumbo sacral region was  done which showed fea-
tures suggestive of a Chordoma attached to the sacrum at S4 and
S5. The tumour was  seen extending both posterior to the sacrum
which was  clinically evident and anterior to it, in the retro rectal
space Fig. 1.
F.N.A.C. of the swelling was done which showed features sug-
gestive of CHORDOMA.
4. Treatment
We  decided to approach the tumour using a posterior approach.
The patient was  in prone position with hips raised. Using a longi-
tudinal incision over the tumour, ﬂaps were raised to visualise it.
The tumour was  dissected free from surrounding structures and
its attachment to the sacrum was visualised. A partial sacrectomy
was done, removing s3, s4 and s5. After the sacral attachment was
released, the tumour was excised in toto, by using the retrorectal
pad of fat as a dissection plane (Figs. 2 and 3).
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Fig. 1. A 12 cm × 8 cm heterogenous mass lesion arising in the retrorectal space
involving the sacrum (s3–s5), coccyx with pre-, paravertebral, intraspinal and pos-
terior spinal components. Fat planes with the rectum well preserved.
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Fig. 3. The excised specimen.
Fig. 4. 100×–200×-large cells with abundant vacuolated cytoplasm, a partially
vesicular nuclei and few showing prominent nucleoli resembling physalliferous
cells.Fig. 2. A plane being created between the swelling and the skin.
. Pathology
An irregular grey brown to grey black specimen with soft tissue
nd bony bits measuring 12 cm × 8.5 cm × 5 cm.  Features sugges-
ive of a Chondroid chordoma.
IHC – cytokeratin, s100 and EMA  positive Figs. 4 and 5.
. Discussion
Tumours that occur in the retrorectal space comprise an uncom-
on and mixed group. They are estimated at one in every 40,000
ospital admissions. Retrorectal tumours maybe classiﬁed as con-
enital, neurogenic, osseous or miscellaneous.4 Chordomas are
olid malignant tumours that arise from vestiges of the foetal
otochord, usually from within the vertebral bodies. As the spine
evelops, notochordal remnants are relegated to the intervertebral
egions where they evolve into the nucleus pulposus. This explains
hy chordomas are in the midline or the paramedian location.5he estimated yearly chordoma incidence is 0.5 cases per million
nhabitants.
They account for 2–4% of all primary malignant bone tumours
nd are the most common primary malignant sacral tumour, withFig. 5. Tumour cells positive for s100.
the exception of lymphoproliferative disease. They occur between
4th and 7th decade, peak in the 5th decade with a male to female
ratio of 2–3:1.5Clinical signs and symptoms may  vary depending on the loca-
tion,the size of the tumour and the extent of neural invasion.
Symptoms of sacral chordomas are indolent and include pain,
numbness, constipation, weakness and incontinence. Common
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ocations are the sacrococcygeus and the spheno occipital regions,
nywhere along the vertebral column, not in the extremities.
Macroscopically, sacrococcygeal chordomas are usually well
emarcated by a pseudocapsule. Most of them involve the bone
nd the surrounding soft tissue and skeletal muscle almost always.
he cut surface of the tumour is characteristically soft, gelatinous,
ucoid, and haemorrhagic.9 Histological features include a mix-
ure of epithelioid and physaliferous cells. Chordomas are classiﬁed
nto classical or conventional, chondroid and de-differentiated
ypes. Most common is chondroid type and de-differentiated type
as the worst prognosis amongst them.
The appearance of localised growth could be misleading and
oft tissue invasion is often missed in a CT for chordoma. Contrast-
nhanced MRI  is the gold standard in imaging. The combination of
igh T2 signal intensity and a lobulated sacral mass that contains
reas of haemorrhage and calciﬁcation is strongly suggestive of a
hordoma.5
The curative treatment of chordomas is en bloc surgical
esection with negative margins. It is associated with long-term
isease control and potential cure. But most often, due to the loca-
ion, size and the extent of the tumour, margin free resection is
ot possible. The expected local failure rate in case of a marginal
esection is 70%.6
Local recurrences, however, have often been observed even
fter total en bloc resection. Although the anterior approach is
trongly recommended for sacral chordoma tumours, the poste-
ior approach is adequate for total resection using retrorectal fat
issue as a cleavage line between tumour and rectum.
Despite surgical treatment, there has been a need to resort to
adiotherapy in combination with surgery for positive or close mar-
ins and even as the deﬁnitive treatment modality for unresectable
esions. There are multiple modalities of RT such as proton beam
adiation therapy, carbon ion radiation therapy, IMRT. At doses up
o 40–60 cGy, however, local control at 5 years with conventional
hotobeam radiation therapy does seem to be in 10–40% range.7,8
Chemotherapy has never played a role in the disease. Studies
how that most patients responded to 800 mg  Imatinib daily. The
possibility that an antiangiogenic effect maybe useful clinically is
being explored.6
Prognosis depends on the resection of the tumour in surgery
and postoperative treatment. Although metastases also may  occur,
most patients who succumb to the disease do so because of local
recurrences. 5 year survival rate is 51% and 10 year survival rate is
35%.9
7. Conclusion
Chordoma is a slow growing, malignant tumour of the bone
arising from the notochordal remanants. They occur more in
men  than in women. Surgical resection with negative margins
is the treatment of choice. Radiotherapy is useful in cases with
negative margins or when the disease is unamenable to sur-
gical treatment. Chemotherapy is used as a supportive care.
Prognosis depends on the surgical resection of the tumour
with postoperative radiotherapy with or without chemother-
apy.
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Key learning points
• Chordomas are rare aggressive tumours from notochordal remnants.
• Enbloc excision with negative margins is the treatment of choice.
• Chemotherapy and radiotherapy do not have a deﬁnitive line of management in these tumours.
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